{"denoms":[{"counts":[{"groupId":"OG000","value":"0"}],"units":"Participants"}],"description":"Blood samples were planned to be collected for the analysis of hematology parameters including basophils, eosinophils, hematocrit, MCHC, MCH, MCV, monocytes, seg neutrophils, RBC count and reticulocytes. Baseline value was defined as the most recent, non-missing value from a local laboratory prior to the first dose of study treatment. Change from Baseline was defined as any visit value minus Baseline value. This analysis was planned but not performed for Part 2 as the study was terminated early during Part 1.","groups":[{"description":"Participants with GCB-DLBCL-mutant and wild type, TFL-mutant and wild type as well as participants with MM were planned to be enrolled in Part 2 of the study. Participants enrolled in Part 2 were planned to receive RP2D .","id":"OG000","title":"Part 2: All Participants"}],"populationDescription":"All Subjects Population. Data was not collected in Part 2 as no participant was enrolled in Part 2.","reportingStatus":"POSTED","timeFrame":"Baseline and up to 3.2 years","title":"Part 2: Number of Participants With Worst Case Changes From Baseline in Hematology Parameters","type":"SECONDARY"}